TNGX News and Press, Tango Therapeutics Inc. From 10/20/22

H.C. Wainwright has started Tango Therapeutics ( NASDAQ: TNGX ) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets th...

BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentation as posters at the EO...

Best Penny Stocks To Buy According To Insiders On their own, penny stocks are some of the most volatile and carry some of the biggest potential for significant gains quickly. Over the last few months, traders have seen explosive gains upward of thousands of percentage points. This isn&#...

CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for poster presentation at ...

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Offic...

Tango Therapeutics press release ( NASDAQ: TNGX ): Q2 GAAP EPS of -$0.28 beats by $0.03 . Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M . For further details see: Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor – – Received Orphan Drug Designation in US for the treatment of malignant peripheral nerve sheath tumors with TNG908 &#...

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Office...

Tango Therapeutics (NASDAQ:TNGX) joined the Russell 2000, Russell 3000 and Russell Microcap Indexes as part of the 2022 Russell indexes annual reconstitution. Changes were effective after the U.S. market closed on June 24, 2022. TNGX shares are trading ~8% higher pre-market For further...

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company was added to the Russell 2000 ® , Ru...